Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

ERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosis.

Gay-Bellile M, Romero P, Cayre A, Véronèse L, Privat M, Singh S, Combes P, Kwiatkowski F, Abrial C, Bignon YJ, Vago P, Penault-Llorca F, Tchirkov A.

J Pathol Clin Res. 2016 Jul 13;2(4):234-246.

2.

The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.

Mahammedi H, Planchat E, Pouget M, Durando X, Curé H, Guy L, Van-Praagh I, Savareux L, Atger M, Bayet-Robert M, Gadea E, Abrial C, Thivat E, Chollet P, Eymard JC.

Oncology. 2016;90(2):69-78. doi: 10.1159/000441148.

PMID:
26771576
3.

Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.

Nabholtz JM, Chalabi N, Radosevic-Robin N, Dauplat MM, Mouret-Reynier MA, Van Praagh I, Servent V, Jacquin JP, Benmammar KE, Kullab S, Bahadoor MR, Kwiatkowski F, Cayre A, Abrial C, Durando X, Bignon YJ, Chollet P, Penault-Llorca F.

Int J Cancer. 2016 May 1;138(9):2274-80. doi: 10.1002/ijc.29952.

PMID:
26649807
4.

Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.

Pouget M, Abrial C, Planchat E, Van Praagh I, Arbre M, Kwiatkowski F, Dubray-Longeras P, Devaud H, Dohou J, Herviou P, Mahammedi H, Durando X, Chollet P, Mouret-Reynier MA.

Oncology. 2015;89(6):319-31. doi: 10.1159/000437230.

PMID:
26457979
5.

BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib.

Dufour R, Daumar P, Mounetou E, Aubel C, Kwiatkowski F, Abrial C, Vatoux C, Penault-Llorca F, Bamdad M.

Sci Rep. 2015 Aug 3;5:12670. doi: 10.1038/srep12670.

6.

15-Lipoxygenases regulate the production of chemokines in human lung macrophages.

Abrial C, Grassin-Delyle S, Salvator H, Brollo M, Naline E, Devillier P.

Br J Pharmacol. 2015 Sep;172(17):4319-30. doi: 10.1111/bph.13210.

7.

Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?

Wang-Lopez Q, Chalabi N, Abrial C, Radosevic-Robin N, Durando X, Mouret-Reynier MA, Benmammar KE, Kullab S, Bahadoor M, Chollet P, Penault-Llorca F, Nabholtz JM.

Crit Rev Oncol Hematol. 2015 Jul;95(1):88-104. doi: 10.1016/j.critrevonc.2015.02.011. Review.

PMID:
25900915
8.

Is it important to adapt neoadjuvant chemotherapy to the visible clinical response? An open randomized phase II study comparing response-guided and standard treatments in HER2-negative operable breast cancer.

Wang-Lopez Q, Mouret-Reynier MA, Savoye AM, Abrial C, Kwiatkowski F, Garbar C, DuBray-Longeras P, Eymard JC, Lebouedec G, Vanpraagh I, Penault-Llorca F, Chollet P, Cure H.

Oncologist. 2015 Mar;20(3):243-4. doi: 10.1634/theoncologist.2014-0400.

9.

Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.

Mombelli S, Kwiatkowski F, Abrial C, Wang-Lopez Q, de Boissieu P, Garbar C, Bensussan A, Curé H.

Oncology. 2015;88(5):261-72. doi: 10.1159/000368557.

PMID:
25573741
10.

Neurotoxicity as a prognostic factor in patients with metastatic breast cancer treated with ixabepilone as a first-line therapy.

Durando X, Dalenc F, Abrial C, Mouret-Reynier MA, Herviou P, Kwiatkowski F, Chollet P, Roche H, Thivat E.

Oncology. 2015;88(3):180-8. doi: 10.1159/000367808.

PMID:
25472499
11.

The role of tomosynthesis in breast cancer staging in 75 patients.

Mercier J, Kwiatkowski F, Abrial C, Boussion V, Dieu-de Fraissinette V, Marraoui W, Petitcolin-Bidet V, Lemery S.

Diagn Interv Imaging. 2015 Jan;96(1):27-35. doi: 10.1016/j.diii.2014.06.010.

12.

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.

Nabholtz JM, Abrial C, Mouret-Reynier MA, Dauplat MM, Weber B, Gligorov J, Forest AM, Tredan O, Vanlemmens L, Petit T, Guiu S, Van Praagh I, Jouannaud C, Dubray-Longeras P, Tubiana-Mathieu N, Benmammar KE, Kullab S, Bahadoor MR, Radosevic-Robin N, Kwiatkowski F, Desrichard A, Cayre A, Uhrhammer N, Chalabi N, Chollet P, Penault-Llorca F.

Ann Oncol. 2014 Aug;25(8):1570-7. doi: 10.1093/annonc/mdu183.

PMID:
24827135
13.

[Taste receptors in the lungs: interesting or anecdotal?].

Grassin-Delyle S, Abrial C, Brollo M, Naline E, Devillier P.

Rev Pneumol Clin. 2014 Jun;70(3):148-55. doi: 10.1016/j.pneumo.2013.11.008. Review. French.

PMID:
24646786
14.

Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors.

Grassin-Delyle S, Naline E, Buenestado A, Faisy C, Alvarez JC, Salvator H, Abrial C, Advenier C, Zemoura L, Devillier P.

Br J Pharmacol. 2014 Jun;171(11):2767-77. doi: 10.1111/bph.12597.

15.

The expression and relaxant effect of bitter taste receptors in human bronchi.

Grassin-Delyle S, Abrial C, Fayad-Kobeissi S, Brollo M, Faisy C, Alvarez JC, Naline E, Devillier P.

Respir Res. 2013 Nov 22;14:134. doi: 10.1186/1465-9921-14-134.

16.

Long-term significance (15 years) of pathological complete response after dose-dense neoadjuvant chemotherapy in breast cancer.

Wang-Lopez Q, Abrial C, Planchat E, Mouret-Reynier MA, Cure H, Gimbergues P, Dubray-Longeras P, Gadea E, Kwiatkowski F, Penault-Llorca F, Chollet P, Durando X.

Breast J. 2013 Jul-Aug;19(4):448-50. doi: 10.1111/tbj.12131. No abstract available.

PMID:
23750595
17.

Temozolomide and unusual indications: review of literature.

Tatar Z, Thivat E, Planchat E, Gimbergues P, Gadea E, Abrial C, Durando X.

Cancer Treat Rev. 2013 Apr;39(2):125-35. doi: 10.1016/j.ctrv.2012.06.002. Review.

PMID:
22818211
18.

Prognostic value of initial tumor parameters after metastatic relapse.

Planchat E, Durando X, Abrial C, Thivat E, Mouret-Reynier MA, Ferrière JP, Pomel C, Kwiatkowski F, Chollet P, Nabholtz JM.

Cancer Invest. 2011 Nov;29(9):635-43. doi: 10.3109/07357907.2011.621911.

PMID:
22011286
19.

Late lines of treatment benefit survival in metastatic breast cancer in current practice?

Planchat E, Abrial C, Thivat E, Mouret-Reynier MA, Kwiatkowski F, Pomel C, Wang-Lopez Q, Chollet P, Nabholtz JM, Durando X.

Breast. 2011 Dec;20(6):574-8. doi: 10.1016/j.breast.2011.07.010.

PMID:
21852136
20.

Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse.

Thivat E, Thérondel S, Lapirot O, Abrial C, Gimbergues P, Gadéa E, Planchat E, Kwiatkowski F, Mouret-Reynier MA, Chollet P, Durando X.

BMC Cancer. 2010 Nov 25;10:648. doi: 10.1186/1471-2407-10-648.

Items per page

Supplemental Content

Loading ...
Support Center